OX40 is a potent co-stimulatory receptor that can potentiate T cell receptor signaling on the surface of T lymphocytes, leading to their activation by a specifically recognized antigen. In particular, OX40 engagement by ligands present on dendritic cells dramatically increases the proliferation, effector function and survival of T cells.
Abstract
OX40 is a potent co-stimulatory receptor that can potentiate T cell receptor signaling on the surface of T lymphocytes, leading to their activation by a specifically recognized antigen. In particular, OX40 engagement by ligands present on dendritic cells dramatically increases the proliferation, effector function and survival of T cells.
Preclinical studies have shown that OX40 agonists increase anti-tumor immunity and improve tumor-free survival. In this study, we performed a Phase I clinical trial using a mouse monoclonal antibody (mAb) that agonizes human OX40 signaling in patients with 
Introduction
Antibodies (Abs) , that target T cell surface proteins, have been shown to restore and enhance the function of tumor-reactive T cells in vivo in tumor-bearing hosts (1) (2) (3) (4) (5) .
The antagonists, anti-CTLA-4 and anti-PD-1, block negative signals to the T cells, while the agonists, anti-4-1BB and anti-OX40, enhance T cell function by increasing costimulation (6) . A phase III clinical trial in patients with metastatic melanoma demonstrated enhanced survival in patients receiving anti-CTLA-4 and these results led to the recent FDA approval of this antibody (7) . Abs directed to PD-1 or PD-1 ligand have produced complete and partial responses as well as durable stable disease in patients with cancer (8, 9) . The strategy of blocking inhibitory T cell pathways has shown clinical activity and there is ample preclinical evidence that T-cell co-stimulation via 4-1BB (10, 11) or OX40 can induce anti-tumor effects (12) (13) (14) (15) .
We completed a translational research study to determine the potential value of immunostimulatory antibody against OX40. OX40 is a TNF-receptor family member that is expressed primarily on activated CD4 + and CD8 + T cells (16) (17) (18) . Preclinical cancer models have shown that anti-OX40 has potent anti-tumor activity against multiple tumor types, which is dependent on both CD4 + and CD8 + T cells (12) (13) (14) (15) . Immunization models have shown that anti-OX40 increased T cell proliferation, effector cytokine production, cytotoxicity, and decreased activation-induced cell death leading to an increase in memory T cells (19) (20) (21) (22) (23) . This report describes the clinical, immunological and anti-tumor effects of an agonist antibody to OX40 in patients with advanced cancer.
Materials and Methods

Clinical trial ID#NCT01644968 :
Clinical trial was designed and performed as described in Supplemental Materials and Methods.
Anti-OX40 mAb (9B12): 9B12 is a murine IgG1, anti-OX40 mAb directed against the extracellular domain of human OX40 (CD134). The mAb was selected as described in Supplemental Material and Methods.
ELISA Assays for Tetanus and KLH:
Recombinant tetanus toxoid C fragment, (Roche), at 2ug/ml, or KLH (Biosyn Corp), at 10ug/ml, was absorbed on the surface of 96-well plates (Fisher). Serum samples were then incubated for 1 hour, followed by peroxidase-conjugated goat anti-human IgG, (Jackson Immuno Research Lab). TMB substrate solution (SureBlue TMB, KPL Inc) was added, followed by a stopping solution (85% O-Phosphoric Acid, Fisher).
Spectrophotmetry measurements were made at 450nm (Wallac Victor2 spectrophotometer, Perkin Elmer).
ELISA Assay for Measurement of Anti-OX40 (CD134) in Human Serum:
Titers in human serum were measured as indicated in Supplemental Material and Methods.
Flow Cytometry:
Peripheral blood mononuclear cells (PBMC) were obtained from patients and cryopreserved samples were used for flow cytometry studies. The fluorochrome-labeled antibodies to CD3, CD4, CD8, CD95, HLA-DR, CD45RA, CCR7 and Ki-67 were purchased from BD Pharmingen, Foxp3 and CXCR5 from eBioscience, CD28 from Beckman Coulter, CD25 from Miltenyi Biotech and CD38, OX40 from BioLegend and Streptavidin AF-700 from Invitrogen. Intracellular staining was performed using the Fix/Perm kit from eBioscience according to the manufacturer's instructions. To prevent the interference of HAMA with staining, cells were preincubated with the mAb anti-OX40 (9B12). Detection of anti-OX40 binding was performed on fresh PBMCs using an anti-mouse IgG and FITC-labeled anti-rat IgG (Invitrogen). Stained cells were analyzed on an LSRII or the FACS Aria (BD Biosciences). Data analysis was performed using either Winlist (Verity Software House) or FACSDiva (Becton Dickinson) software.
Tumor-Specific T cell Assays:
Tumor-specific reactivity before and after anti-OX40 administration was assessed in PBMC from 3 melanoma patients. Autologous or HLA-matched melanoma cells were cocultured with PBMC at a PBMC:tumor ratio of 8:1 for five days. IFN-γ in the supernatant was quantified using an IFN-γ ELISA kit (BD Biosciences). Western blot: FEMX (ATCC) or HEK 293 (ATCC) cells cell lysate were heated to 100 o C in gel sample buffer with SDS for 5 minutes and 15 ug of protein were separated by electrophoresis on a 10% SDS PAGE gel. Proteins were transferred to nitrocellulose. The blocked membrane was incubated with patient sera, then with a peroxidase-conjugated secondary Ab, and exposed with ECL Western Blotting substrate (Pierce).
T cell Proliferation Assay
Cryopreserved PBMC (12 Arm A samples and 11 Arm B samples), 1x10 5 PBMC per well, were stimulated with 0.5µg/ml of anti-CD28/anti-CD49d (BD Biosciences) and with tetanus toxoid antigen (EMD Calbiochem) at 1ug/ml for 4 days. Cells were then labeled with [ 
Statistical Analyses:
Ki-67 Analyses: For each cell population the mean differences between treatment cohorts at study days 8 and 15 were compared using one-way analysis of variance (ANOVA) on the log 10 fold-change from baseline. The log 10 transformation was performed to satisfy statistical model assumptions. Comparisons between cohorts were not adjusted for multiple comparisons due to the exploratory nature of the analyses. Mean differences in fold-change between responders and non-responders at each study day were analyzed using one-way ANOVA. Analyses were performed using JMP version 9 (SAS Institute). dilution at which the sera would be considered negative (endpoint dilution). A best-fit curve generated by a 1-phase decay model was used to determine the OD values for the bottom plateau for each ELISA plate. The mean for all of the plateaus on the plate + 4 standard deviations was used as the cut-off OD. The dilution at which each curve intersected the cutoff is the endpoint dilution (titer) for that curve. The two arms from all three cohorts were compared using a two-tailed Mann-Whitney (Wilcoxon rank-sum test) analysis to determine whether the mean fold-change increased significantly from baseline between the two arms.
Tetanus and KLH
T-cell Proliferation Assay:
A two-tailed Mann-Whitney (Wilcoxon rank-sum test) was used to determine whether the mean thymidine incorporation was significantly increased when comparing the pre-treatment levels to either day 43 for Arm A or day 15 for Arm B.
Tumor-specificity Assay: IFNγ secretion from supernatants containing either pretreatment or post-treatment PBMC co-cultured with either autologous, HLA-mismatched cell line, or flu, were compared using a one-tailed unpaired t-test to determine statistical significance.
Results
Clinical Results
Patients with metastatic solid malignancies refractory to conventional therapy were enrolled in a phase 1 dose-escalation study using the 9B12 murine agonistic antihuman OX40 mAb, Trial ID#NCT01644968 (see Supplemental Figure 1 Toxicity Assessment: Twenty-eight of 30 patients received all three planned anti-OX40 doses at the assigned dose level. Table 1 summarizes the toxicities related to anti-OX40.
Most toxicity was grade 1 or 2 with the exception of lymphopenia where grade 3 and 4 events were observed. Lymphopenia, fatigue, rash and flu-like symptoms with fever and chills were the most common toxicities; they usually started after the last anti-OX40 dose and generally resolved 72 hours later. Lymphopenia was transient (Supplemental Figure   2 ), and resolved by day 15 in cohort 1 and day 28 in cohort 2. Anti-OX40 was well tolerated and the MTD was not reached.
Pharmacokinetics and Human Anti-mouse Ab (HAMA) Production:
There was a dosedependent increase in peak serum anti-OX40 levels after the first and third doses (serum was not assessed following the second dose), and decreased thereafter (Supplemental Figure 3 ). Peak anti-OX40 levels were observed 2 hours after the third dose. Anti-OX40 Ab was detected on the surface of PBMC when examined ex vivo by flow cytometry, using an anti-mouse specific Ab. Between 9.9 to 26.9% of CD4 T cells and 0.6 to 7.8% of CD8 T cells were positive using this technique (Supplemental Figure 4) . All but one patient tested had high serum HAMA levels on day 28 (data not shown). There was no increased toxicity or HAMA titers as the anti-OX40 dose increased.
Tumor Regression: Figure 1A shows a waterfall plot for best response by RECIST after anti-OX40. No patient achieved a partial response by RECIST (>30% overall tumor shrinkage). However, at least one tumor nodule regressed in 12 patients and no change in the measurement of target lesions was observed in 6 additional individuals during the 57-day observation period. Regression and SD were observed in patients with melanoma, renal cancer, squamous cell carcinoma of the urethra, prostate cancer and cholangiocarcinoma. The longest interval of stable disease lasted 470 days in a patient with renal cancer, who received no other therapy during that time. Some individuals had a decrease in measurable lesions at day 29, but had progression by day 57. following anti-OX40. Mixed responses (e.g.: simultaneous regression of at least one tumor deposit and progression at other sites) were observed in two patients with melanoma and two patients with renal cancer.
Immunologic Results
Anti-OX40 increases proliferation of CD4 FoxP3
neg and CD8 T lymphocytes: To determine the effects of anti-OX40 on T cells, we performed multi-color flow cytometry with antibodies that recognized CD3, CD4, CD8, CD95, CD25, FoxP3, CD28, and Ki-67.
Changes in T-cell subpopulation frequencies were determined using FCOM analysis tool in Winlist (24) and statistically significant changes were assessed using exhaustive expansion analysis (25) . Ki-67 expression, which is present only within proliferating cells, was measured since OX40 agonists are known to increase T-cell proliferation and this was the only marker that was associated with significant changes in the exhaustive expansion analysis referenced above. Changes in Ki-67 expression for both CD4 and T reg in the PBL was less than 20%, while more than 50% of T reg from TIL expressed OX40 ( Figure 3B-C) . Moreover, the MFI for OX40 was up to 16 fold higher in TIL compared to PBL T reg , suggesting that the anti-OX40 may modulate T reg function in the tumor.
Anti-OX40 induces a transient decrease of follicular helper CD4 + T cells in the PBL:
Anti-OX40 increased anti-TT and anti-KLH Abs, suggesting enhanced activity in T follicular helper cells. We analyzed the percentage of CD4 
Antibody and T cell responses to reporter antigens:
Patients at all dose levels were randomized into two groups; Arm A patients received KLH on day 1 (the same day anti-OX40 started) followed by a tetanus vaccine on day 29, and Arm B patients received tetanus on day 1 and KLH on day 29. Peak antibody levels to KLH and tetanus were assessed 15 days after immunization, which was either on day 15 
well tolerated; mild to moderate side effects included a brief period of lymphopenia, fatigue, fever/chills, and mild rashes. The MTD was not reached within the dose levels tested. There was tumor shrinkage in 12/30 patients following just one cycle, although there were no responses using RECIST. The major limitation of this mouse mAb was the induction of HAMA, which precluded the administration of multiple cycles. Despite this limitation, much was learned about the immunomodulatory effects of OX40. The results of this proof-of-principle study will help in the design and monitoring of future clinical trials using humanized OX40 agonists that we anticipate will lead to increased immunologic activation and greater clinical activity.
The immune stimulatory effects of anti-OX40 observed in humans are similar to those described in mice and monkeys (31, 32) . A significant increase in proliferation of 
